PE20091258A1 - Derivados de piridina como activadores de la guanilato ciclasa soluble - Google Patents
Derivados de piridina como activadores de la guanilato ciclasa solubleInfo
- Publication number
- PE20091258A1 PE20091258A1 PE2008002003A PE2008002003A PE20091258A1 PE 20091258 A1 PE20091258 A1 PE 20091258A1 PE 2008002003 A PE2008002003 A PE 2008002003A PE 2008002003 A PE2008002003 A PE 2008002003A PE 20091258 A1 PE20091258 A1 PE 20091258A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- pyridine derivatives
- pyridin
- phenyl
- methyl
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 3
- 101710095468 Cyclase Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 ALLYL Chemical class 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRIDINA DE FORMULA (I), DONDE R1 Y R2 SON H, HALO, CF3, ALQUILO C1-C4, ALILO; Y ES FENILO, PIPERIDINA, ENTRE OTROS; R4 ES H O METILO; Z ES (CH2)2, OCH2 O ESTA AUSENTE; A, J Y L SON CH O N; R5 ES H, CH3, ALCOXI C1-C4, ENTRE OTROS; R6 ES H O CH3; X ES (a); R8 ES H O HALO; R9 ES H, HALO, OCF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 1-[6-(2-(4-(4-CIANOFENOXI)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ACIDO 1-[6-(2-(2-METIL-4-(4-TRIFLUOROMETOXIFENIL)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE LA GUANILATO CICLASA SOLUBLE (sGC) Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES CARDIOVASCULARES TALES COMO HIPERTENSION ARTERIAL, ATEROESCLEROSIS, ANGINA DE PECHO, ENTRE OTROS
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0723629A GB0723629D0 (en) | 2007-12-03 | 2007-12-03 | Compounds |
| GB0813714A GB0813714D0 (en) | 2008-07-25 | 2008-07-25 | Compounds |
| GB0816960A GB0816960D0 (en) | 2008-09-16 | 2008-09-16 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091258A1 true PE20091258A1 (es) | 2009-09-12 |
Family
ID=40717321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008002003A PE20091258A1 (es) | 2007-12-03 | 2008-12-01 | Derivados de piridina como activadores de la guanilato ciclasa soluble |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR069517A1 (es) |
| PE (1) | PE20091258A1 (es) |
| TW (1) | TW200938529A (es) |
| UY (1) | UY31507A1 (es) |
| WO (1) | WO2009071504A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5298129B2 (ja) | 2007-09-06 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化因子 |
| WO2009081970A1 (ja) * | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | ヘテロ環置換ピリジン誘導体の製造方法 |
| EP2264017A4 (en) | 2008-04-04 | 2011-07-27 | Takeda Pharmaceutical | Heterocyclic derivative and its use |
| WO2010015652A2 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| MA33984B1 (fr) | 2010-02-05 | 2013-02-01 | Bayer Ip Gmbh | Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| US20130096160A1 (en) * | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| ES2549979T3 (es) | 2010-05-26 | 2015-11-03 | Adverio Pharma Gmbh | El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS) |
| WO2011161099A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| WO2012122340A1 (en) * | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| CN104245663B (zh) | 2012-04-16 | 2016-10-26 | 东亚荣养株式会社 | 二环化合物 |
| US8906904B2 (en) * | 2012-09-07 | 2014-12-09 | Boehringer Ingelheim International Gmbh | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| WO2014095249A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746260A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| EP2746259A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
| CA2923393A1 (en) | 2013-09-05 | 2015-03-12 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| WO2015056663A1 (ja) | 2013-10-15 | 2015-04-23 | トーアエイヨー株式会社 | ４－アミノメチル安息香酸誘導体 |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625601A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| SG11201700507XA (en) | 2014-07-22 | 2017-02-27 | Boehringer Ingelheim Int | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
| CN105980373A (zh) * | 2014-09-05 | 2016-09-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 新的可溶性鸟苷酸环化酶活化剂及它们的用途 |
| CR20170102A (es) | 2014-09-19 | 2017-07-17 | Glaxosmithkline Ip Dev Ltd | Nuevos activadores de la guanilato ciclasa soluble y su uso |
| JP6748113B2 (ja) | 2015-05-06 | 2020-08-26 | バイエル・ファルマ・アクティエンゲゼルシャフト | 全身性硬化症（ＳＳｃ）に付随する指潰瘍（ＤＵ）を治療するための単独のまたはＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤、ｓＧＣ活性化剤の使用 |
| CA2989740C (en) | 2015-07-23 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof |
| EP3390386A1 (en) | 2015-12-18 | 2018-10-24 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
| CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| TW202015676A (zh) | 2018-05-15 | 2020-05-01 | 德商拜耳廠股份有限公司 | 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CA3258617A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Ag | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
-
2008
- 2008-12-01 TW TW097146531A patent/TW200938529A/zh unknown
- 2008-12-01 WO PCT/EP2008/066514 patent/WO2009071504A1/en not_active Ceased
- 2008-12-01 UY UY31507A patent/UY31507A1/es unknown
- 2008-12-01 AR ARP080105233A patent/AR069517A1/es unknown
- 2008-12-01 PE PE2008002003A patent/PE20091258A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR069517A1 (es) | 2010-01-27 |
| UY31507A1 (es) | 2009-07-17 |
| TW200938529A (en) | 2009-09-16 |
| WO2009071504A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091258A1 (es) | Derivados de piridina como activadores de la guanilato ciclasa soluble | |
| PE20091491A1 (es) | Compuestos novedosos que son inhibidores de erk | |
| PE20091002A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| PE20091033A1 (es) | Derivados de nicotinamida como agentes anticancerosos y su preparacion | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20080453A1 (es) | Derivados de fenil.oxi-fenil-pirimidinona en el tratamiento de malaria | |
| PE20081120A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp) | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| PE20051170A1 (es) | DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
| PE20110566A1 (es) | Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1 | |
| PE20081636A1 (es) | Inhibidores de antranilamida para aurora quinasa | |
| PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
| PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
| PE20120911A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
| PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| PE20040864A1 (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |